ScheDUle AN Appointement

Jeni Beh Janci, PhD

Program Director, Catalyst Program, and EIR, Blackstone LaunchPad powered by Techstars

Jeni began her life science career in the start-up biotech industry before earning her Ph.D. at University of California, Berkeley in Molecular and Cell Biology. She returned to industry, where she consulted to pharmaceutical companies employing Quantitative Systems Phamacology. She joined UCSF Catalyst Program in 2019, where she manages the diagnostics, digital health, and biotools tracks. 

Charles Hart, PhD

Director, Catalyst Program

From 2004 to 2017 he was at Threshold Pharmaceuticals and responsible for both in vitro and in vivo preclinical translational studies. He was also project leader for the global clinical development program for the hypoxia-targeted anticancer drug evofosfamide (TH-302), a partnership with Merck KGaA. Prior to joining Threshold, Charles was at Galileo Pharmaceuticals (2001 to 2004), Signature Bioscience (2000 to 2001), and Affymax (1990 to 2000). Charles received his PhD in molecular biology and genetics from Yale University in 1987, and completed a postdoctoral fellowship at the University of Strasbourg, France in 1990.

Michael Lesh, MD

Executive Director, Health Technology Innovation

Michael D. Lesh, MD is a physician, scientist and entrepreneur. He is currently Executive Director of Health Technology Innovation in the Office of the Vice Chancellor for Business Development, Innovation and Partnership at UCSF whose mission is to commercialize the University's research and inventions. Dr. Lesh focuses on high value digital health and medical device opportunities, mentors entrepreneurs and start-ups.

Dr. Lesh joined the faculty at UCSF, where he was Chief of Cardiac Electrophysiology. He pioneered a number of procedures for catheter ablation of cardiac arrhythmias, and is the author of over 300 scientific papers, book chapters and books. Dr. Lesh holds over 200 patents issued or pending, including the fundamental method for pulmonary vein isolation (PVI) for atrial fibrillation, and left atrial appendage occlusion (LAAO) to prevent stroke. Since 1997, Dr. Lesh has founded a number of medical device companies based on his inventions. He now serves as a mentor to numerous entrepreneurs and participates as an “angel" investor in early stage companies across the healthcare space.